Rheumatology International

, Volume 38, Issue 7, pp 1199–1205 | Cite as

MicroRNA values in children with rheumatic carditis: a preliminary study

  • Gokhan Gumus
  • Dilek GirayEmail author
  • Onur Bobusoglu
  • Lulufer Tamer
  • Derya Karpuz
  • Olgu Hallioglu


MicroRNAs (miRNAs) are fine regulators of gene expression which participate in the regulation of almost every phase of cell physiology, including development of immune cells and adjustment of immune response. In the studies with in vitro/in vivo model systems, specific miRNAs are revealed to have various roles in cardiovascular development and physiological functions. Furthermore, some studies have been done to understand the role of miRNAs about myocarditis, heart failure and coronary artery diseases. miRNAs crucial role in the pathogenesis of other rheumatic diseases have been investigated, however rheumatic carditis was not studied. The aim of this study is to assess values of miRNAs in children with rheumatic carditis and compare them with healthy children. This study included 36 children with rheumatic carditis (mean aged 12.1 ± 2.1 years) and age–gender matched 35 healthy controls (mean aged 11.1 ± 2.3 years). Conventional echocardiography was performed to all subjects. Using real-time polymerase chain reaction, the expression of some miRNAs (hsamiR-16-5p, hsa-miR-221-3p, hsa-miR-223-3p, hsa-miR-10a-5p, hsa-miR-24-3p, hsamiR-92a-3p, hsa-iR-320a, hsa-miR-21-5p, hsa-miR-155-5p, hsa-miR-132-3p, hsamiR-146a-5p, hsa-miR-499a-5p, hsa-miR-1, hsa-miR-125, hsa-miR-196a-5p, hsa-miR-130b-3p, hsa-miR-133b, hsa-miR150-5p,hsa-miR-204-5p, hsa-miR-203a) were analyzed. hsa-miR-16-5p(-1.46 fold, p < 0.01), hsa-miR-223-3p(-1.46 fold, p < 0.01), and hsa-miR-92a-3p(-1.27 fold, p < 0.05) expressions in the patients were lower than those of controls, whereas other examined miRNAs did not differently express between the groups. Results of the study demonstrated that significant downregulation of hsa-miR-16-5p, hsa-miR-223-3p and hsa-miR-92a-3p in children with rheumatic carditis. Since, this is the first study in children with rheumatic carditis, further studies are needed for lightening whether these miRNAs might be helpful as biomarkers.


microRNA Rheumatic carditis Valve involvement 



This study was supported by Mersin University Scientific Research Projects Management Unit with project number 2015-1TP31251. The study was presented in 50th Annual Meeting of the AEPC in Rome 2016 as an abstract.

Author contributions

OB, LT and OH designed the study. DG, GG and DK searched databases and performed the selection of studies; DG wrote the initial draft of manuscript, edited and revised the manuscript at all stages of its production, reviewed the literature and managed the patients. OH and LT contributed to editing of manuscript, reviewed the literature, and approved the last version. All co-author read and approved the final version, and agreed to take full responsibility for its all parts.

Compliance with ethical standards

Conflict of interest

All authors declare no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the local ethics committee of the Mersin University (2014/244).

Informed consent

An informed consent was obtained from parents of the patients for publication.


  1. 1.
    Carapetis JR, Steer AC, Mulholland AK, Weber M (2005) The global burden of group A streptococcal diseases. Lancet Infect Dis 5:685–94CrossRefPubMedGoogle Scholar
  2. 2.
    Flynt AS, Lai EC (2008) Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet 9:831–842CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Rota R, Ciarapica R, Giordano A, Miele L, Locatelli F (2011) MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality. Mol Cancer 10:120CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11:597–610CrossRefPubMedGoogle Scholar
  5. 5.
    Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Cai B, Pan Z, Lu Y (2010) The roles of microRNAs in heart diseases: a novel important regulator. Curr Med Chem 17:407–411CrossRefPubMedGoogle Scholar
  7. 7.
    WHO Study Group on Rheumatic Fever and Rheumatic Heart Disease (‎2001: Geneva, Switzerland) & World Health Organization (‎2004) Rheumatic fever and rheumatic heart disease: report of a WHO expert consultation, Geneva, 20 October–1 November 2001. World Health Organization, Geneva.
  8. 8.
    Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513–10518CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N et al (2008) Serum microRNAs are promising novel biomarkers. PLoS One 3:3148CrossRefGoogle Scholar
  10. 10.
    Cortez MA, Calin GA (2009) MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 9:703–711CrossRefPubMedGoogle Scholar
  11. 11.
    Sonkoly E, Pivarcsi A (2009) Advances in microRNAs: implications for immunity and inflammatory diseases. J Cell Mol Med 13(1):24–38CrossRefPubMedGoogle Scholar
  12. 12.
    Lu LF, Liston A (2009) MicroRNA in the immune system, microRNA as an immune system. Immunology 127(3):291–298CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ciancio G, Ferracin M, Negrini M, Govoni M (2013) The role of micro-RNAs in rheumatic diseases: an update. Innovative Rheumatol. CrossRefGoogle Scholar
  14. 14.
    Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS (2006) MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 281:18277–18284CrossRefPubMedGoogle Scholar
  15. 15.
    Faraoni I, Antonetti FR, Cardone J, Bonmassar E (2009) miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 1792:497–505CrossRefPubMedGoogle Scholar
  16. 16.
    Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C et al (2010) Circulating microRNAs in patients with coronary artery disease. Circ Res 107:677–684CrossRefPubMedGoogle Scholar
  17. 17.
    Zidar N, Boštjančič E, Glavač D, Stajer D (2011) MicroRNAs, innate immunity and ventricular rupture in human myocardial infarction. Dis Markers 31:259–265CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Zidar N, Jeruc J, Balazic J, Stajer N (2005) Neutrophils in human myocardial infarction with rupture of the free wall. Cardiovasc Pathol 14:247–250CrossRefPubMedGoogle Scholar
  19. 19.
    De Rosa S, Fichtlscherer S, Lehmann R, Assmus B, Dimmeler S, Zeiher AM (2011) Transcoronary concentration gradients of circulating microRNAs. Circulation 124:1936–1944CrossRefPubMedGoogle Scholar
  20. 20.
    Fu JD, Rushing SN, Lieu DK, Chan CW, Kog CW, Geng L, Wilson KD, Chiamvimonat N et al (2011) Distinct roles of microRNA-1 and -499 in ventricular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes. PLoS One 6(11):27417CrossRefGoogle Scholar
  21. 21.
    Hosoda T, Zheng H, Cabral-da-Silva M, Sanada F, Ide-Iwata N, Ogorek B, Ferreira-Martins J, Arranto C et al (2011) Human cardiac stem cell differentiation is regulated by a mircrine mechanism. Circulation 123(12):1287–1296CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, Wagner DR, Staessen JA, Heymans S, Schroen B (2010) Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 3:499–506CrossRefPubMedGoogle Scholar
  23. 23.
    Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Schellings MW, Barenbrug P et al (2009) miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 104:170–178CrossRefPubMedGoogle Scholar
  24. 24.
    Van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN (2006) A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103:18255–18260CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M et al (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:13944–13949CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K et al (2009) MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324:1710–1713CrossRefPubMedGoogle Scholar
  27. 27.
    Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC (2007) Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 100:1164–1173CrossRefPubMedGoogle Scholar
  28. 28.
    Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, Mercatanti A, Hammond S, Rainaldi G (2006) MicroRNAs modulate the angiogenic properties of HUVECs. Blood 108:3068–3071CrossRefPubMedGoogle Scholar
  29. 29.
    Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J (2007) MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116:258–267CrossRefPubMedGoogle Scholar
  30. 30.
    Goddeeris MM, Rho S, Petiet A, Chandra LD, Johnson GA, Meyers EN, Klingensmith J (2008) Intracardiac septation requires hedgehog-dependent cellular contributions from outside the heart. Development 135:1887–1895CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Xu J, Hu Z, Xu Z, Gu H, Yi L, Cao H, Chen J, Tian T, Liang J, Lin Y, Qiu W, Ma H, Shen H, Chen Y (2009) Functional variant in microRNA-196a2 contributes to the susceptibility of congenital heart disease in a Chinese population. Hum Mutat 30:1231–1236CrossRefPubMedGoogle Scholar
  32. 32.
    Zhou B, Rao L, Peng Y, Wang Y, Chen Y, Song Y, Zhang L (2010) Common genetic polymorphisms in pre-microRNAs were associated with increased risk of dilated cardiomyopathy. Clin Chim Acta 411(17–18):1287–1290CrossRefPubMedGoogle Scholar
  33. 33.
    Brian LS, Gloria R, Karin N, Shelley DM, Carmen CS (2013) miRNA expression in pediatric failing human heart. J Mol Cell Cardiol 57:43–46CrossRefGoogle Scholar
  34. 34.
    Ren XP, Wu J, Wang X, Sartor MA, Qian J, Jones K, Nicolaou P, Pritchard TJ, Fan GC (2009) MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 119:2357–2366CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Meisgen F, Xu N, Wei T, Janson PC, Obad S, Broom O, Nagy N, Kauppinen S, Kemény L, Ståhle M, Pivarcsi A, Sonkoly E (2012) MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp Dermatol 21(4):312–314CrossRefPubMedGoogle Scholar
  36. 36.
    Lai NS, Yu HC, Chen HC, Yu CL, Huang HB, Lu MC (2013) Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributed to the immunopathogenesis. Clin Exp Immunol 173(1):47–57CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK (2008) Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 10(4):R101CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Ha T-Y (2011) The role of MicroRNAs in regulatory T Cells and in the immune response. Immune Netw 11(1):11–41CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Müller-Tidow C, Bohlander SK, Tenen DG, Behre G (2010) Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood 115(9):1768–1778CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PediatricsVan Caldıran State HospitalVanTurkey
  2. 2.Department of Pediatric Cardiology, Faculty of MedicineMersin UniversityMersinTurkey
  3. 3.Department of Medical Biochemistry, Faculty of MedicineMersin UniversityMersinTurkey

Personalised recommendations